Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study
- PMID: 24799541
- DOI: 10.1542/peds.2013-3916
Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study
Abstract
Background and objectives: Children with Down syndrome (DS) are at significant risk for respiratory syncytial virus (RSV) infection and related hospitalization. We compared hospitalization rates due to respiratory tract infection in children with DS aged <2 years who prospectively received palivizumab during the RSV season with a previously published, similar untreated DS birth cohort.
Methods: A total of 532 children with DS who prospectively received palivizumab were assembled from the prospective Canadian RSV Evaluation Study of Palivizumab registry between 2005 and 2012. The untreated group included 233 children with DS derived from a nationwide Dutch birth cohort from 2003 to 2005. Events during the RSV seasons were counted. Poisson regression analysis was performed to compare incidence rate ratios (95% confidence intervals [CIs]) between groups while controlling for observation length and known risk factors for severe RSV infection.
Results: In total, 31 (23 untreated, 8 treated) RSV-related hospitalizations were documented. The adjusted risk of RSV-related hospitalizations was higher in untreated subjects than in palivizumab recipients (incidence rate ratio 3.63; 95% CI, 1.52-8.67). The adjusted risk of hospitalization for all respiratory tract infection (147 events; 73 untreated, 74 treated) was similar (incidence rate ratio untreated versus palivizumab 1.11; 95% CI, 0.80-1.55).
Conclusions: These results suggest that palivizumab is associated with a 3.6-fold reduction in the incidence rate ratio for RSV-related hospitalization in children with DS during the first 2 years of life. A randomized trial is needed to determine the efficacy of RSV immunoprophylaxis in this specific high-risk patient population.
Trial registration: ClinicalTrials.gov NCT00420966.
Keywords: Down syndrome; outcomes; palivizumab; respiratory syncytial virus.
Copyright © 2014 by the American Academy of Pediatrics.
Similar articles
-
Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.Pediatr Infect Dis J. 2014 Feb;33(2):e29-33. doi: 10.1097/INF.0000000000000019. Pediatr Infect Dis J. 2014. PMID: 23989104
-
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. doi: 10.1097/01.inf.0000053885.34703.84. Pediatr Infect Dis J. 2003. PMID: 12671452
-
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.
-
Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?Clin Ther. 2004 Dec;26(12):2130-7. doi: 10.1016/j.clinthera.2004.12.005. Clin Ther. 2004. PMID: 15823776 Review.
-
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602. doi: 10.1002/14651858.CD006602.pub4. Cochrane Database Syst Rev. 2013. PMID: 23633336 Review.
Cited by
-
Clinical practice - latest insights in optimizing the care of children with Down syndrome.Eur J Pediatr. 2023 May;182(5):2027-2039. doi: 10.1007/s00431-023-04890-9. Epub 2023 Mar 10. Eur J Pediatr. 2023. PMID: 36897403 Review.
-
Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series.Hum Vaccin Immunother. 2021 Apr 3;17(4):1235-1238. doi: 10.1080/21645515.2020.1809265. Epub 2020 Sep 22. Hum Vaccin Immunother. 2021. PMID: 32961094 Free PMC article.
-
Pediatric intensive care unit admission due to respiratory syncytial virus: Retrospective multicenter study.Pediatr Int. 2019 Jul;61(7):688-696. doi: 10.1111/ped.13893. Pediatr Int. 2019. PMID: 31107995 Free PMC article.
-
Underlying factors of recurrent infections in patients with down syndrome.North Clin Istanb. 2018 Jan 29;5(2):163-168. doi: 10.14744/nci.2017.69379. eCollection 2018. North Clin Istanb. 2018. PMID: 30374487 Free PMC article. Review.
-
Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.Eur J Pediatr. 2018 Jun;177(6):903-911. doi: 10.1007/s00431-018-3142-x. Epub 2018 Apr 12. Eur J Pediatr. 2018. PMID: 29651734
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical